Evenity (Romosozumab) Sexual Function Impact: What the Evidence Actually Shows

What Romosozumab Actually Does Inside the Body

Romosozumab binds sclerostin, a glycoprotein secreted by osteocytes that normally suppresses bone formation by inhibiting the Wnt/beta-catenin signaling pathway. By neutralizing sclerostin, the drug simultaneously increases bone mineral density through new bone formation and decreases bone resorption markers. The FDA approved it in April 2019 for postmenopausal women at high or very high fracture risk. [1]

The Wnt Pathway and Reproductive Tissue

The Wnt/beta-catenin cascade is expressed in multiple tissue types beyond bone, including the ovary, uterus, and to a smaller extent the testis. [2] Preclinical studies have examined whether sclerostin inhibition in those tissues could have physiological consequences. So far, no clinical evidence links romosozumab to measurable changes in estradiol, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or testosterone concentrations in treated patients.

How the Drug Reaches Systemic Circulation

After subcutaneous injection, romosozumab shows a mean absolute bioavailability of approximately 81% with a median time to peak concentration of five days. [1] Its primary catabolism route is proteolytic degradation, not hepatic cytochrome P450 metabolism. This matters for the sexual-function question: CYP3A4-mediated metabolism of sex steroids remains unaffected by the drug.

What Phase-3 Trials Reported on Sexual Function

Neither the ARCH trial nor the FRAME trial listed sexual dysfunction as a treatment-emergent adverse event at any statistically meaningful frequency. Reviewing the published safety tables from both studies helps place this absence in context.

ARCH Trial (N=4,093)

The ARCH trial, published in the New England Journal of Medicine in 2017, randomized 4,093 postmenopausal women with osteoporosis and a prior vertebral fracture to romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone for 24 months. [3] The primary efficacy result showed a 48% reduction in new vertebral fractures at 24 months with the romosozumab-to-alendronate sequence compared with alendronate alone (6.2% vs. 11.9%; P<0.001). [3] The adverse-event tables in ARCH do not list decreased libido, sexual dysfunction, or genital-tract complaints as events exceeding 1% incidence in either group.

FRAME Trial (N=7,180)

The FRAME trial, also published in 2017 in the New England Journal of Medicine, enrolled 7,180 postmenopausal women and compared romosozumab 210 mg monthly for 12 months with placebo, followed by denosumab in both groups for 12 additional months. [4] At 12 months, romosozumab reduced new vertebral fractures by 73% relative to placebo (0.5% vs. 1.8%; P<0.001). [4] Sexual-function outcomes were not a prespecified endpoint, and no signal appeared in the spontaneous adverse-event reporting.

Phase-2 Dose-Finding Data

A phase-2 randomized controlled trial by McClung et al. (N=419) published in the New England Journal of Medicine in 2014 tested multiple doses of romosozumab (ranging from 70 mg to 210 mg subcutaneously every month or every three months) and included biomarker panels. [5] Serum estradiol levels were not significantly altered at any dose, providing the earliest direct pharmacodynamic reassurance on this point.

The Hormonal Field in the Target Population

Most patients prescribed romosozumab are postmenopausal women, a population in which sexual dysfunction is already common independent of any drug. Prevalence estimates from population-based surveys suggest 40 to 50% of postmenopausal women report at least one sexual complaint, most commonly decreased desire, dyspareunia, or impaired arousal. [6]

Why Attribution Is Difficult

When a postmenopausal woman on romosozumab reports decreased libido, at least five non-drug explanations are more likely than the medication itself:

1. Genitourinary syndrome of menopause (GSM), affecting an estimated 27 to 84% of postmenopausal women depending on diagnostic criteria. [6]
2. Concurrent antidepressant use. Selective serotonin reuptake inhibitors (SSRIs) reduce desire in 30 to 40% of users.
3. Chronic pain from vertebral fractures preceding treatment initiation.
4. Glucocorticoid-induced osteoporosis in patients on long-term prednisone, where the steroid itself suppresses sex hormones.
5. Prior or concurrent bisphosphonate therapy, which does not directly affect libido but accompanies conditions that do.

What the Endocrine Society Guidelines Say

The Endocrine Society's 2019 clinical practice guideline on postmenopausal osteoporosis states that agents targeting bone remodeling pathways do not require baseline or on-treatment sex-hormone monitoring unless the patient has a concurrent hypogonadal condition. [7] That guidance applies to romosozumab. The guideline does not list sexual dysfunction as a monitoring parameter for anti-sclerostin therapy.

Sclerostin Biology in Reproductive Tissues: The Mechanistic Case

A more granular question is whether blocking sclerostin in non-skeletal tissues could theoretically alter reproductive or sexual function. This is an area of active basic science research.

Sclerostin Expression Outside Bone

Sclerostin (encoded by the SOST gene) is predominantly expressed in osteocytes, but lower-level expression has been detected in chondrocytes, kidney tubular cells, and some reproductive tissues. [2] A 2016 study in the Journal of Bone and Mineral Research examined SOST expression in human ovarian follicles and found detectable but low transcript levels, with no correlation to follicular maturation stage. [8] That study did not test the effect of sclerostin blockade on follicular function.

Animal Data on Reproductive Endpoints

Preclinical toxicology studies submitted in support of the FDA's approval of romosozumab included reproductive and developmental toxicology assessments in cynomolgus monkeys. [1] No adverse reproductive outcomes were observed at doses producing approximately ten times the human AUC. The FDA label does not list ovarian, uterine, or hormonal toxicity findings from those studies.

Wnt Signaling and Female Sexual Arousal

Wnt/beta-catenin signaling has roles in vaginal epithelial maintenance and smooth-muscle tone. [2] One might hypothesize that systemic sclerostin inhibition could alter this. No human clinical study has examined vaginal physiology as an outcome during romosozumab treatment. This is a genuine evidence gap.

Clinical Decision Framework: Evaluating Sexual Complaints in a Patient on Romosozumab

Use this stepwise approach when a patient on romosozumab reports a new sexual complaint:

| Step | Action | Key Tools | |------|--------|-----------| | 1 | Establish timeline (did complaints predate romosozumab?) | Patient history, medical records | | 2 | Screen for GSM | Vaginal Health Index, symptom questionnaire | | 3 | Review concurrent medications for known sexual side effects | Drug interaction database | | 4 | Check serum estradiol, FSH, total testosterone, SHBG | Lab panel | | 5 | Assess for depression or anxiety | PHQ-9, GAD-7 | | 6 | If no alternative etiology found, consider stopping romosozumab only after weighing fracture risk | FRAX score, DXA result |

If romosozumab is discontinued early, the patient loses the 12-month anabolic window. Bone mineral density gains begin to reverse within six months without a follow-on antiresorptive. [3] That clinical cost must be weighed against any sexual symptom burden.

Cardiovascular Risk: The Warning That Does Matter

While sexual function data are reassuring, a more pressing safety concern exists for romosozumab. The FDA added a boxed warning in 2019 noting that ARCH showed a higher rate of serious cardiovascular events in the romosozumab group compared with alendronate: 2.5% vs. 1.9% of patients experienced a major adverse cardiovascular event (MACE) through 24 months. [1][3]

Practical Implication

Patients with a myocardial infarction or stroke in the preceding 12 months should not receive romosozumab. [1] This cardiovascular history restriction is far more clinically significant than any theoretical sexual-function concern. Before prescribing, obtain a thorough cardiac history and consider cardiovascular risk calculators such as the ACC/AHA Pooled Cohort Equations. [9]

Romosozumab Compared with Other Osteoporosis Agents on Sexual Function

No head-to-head randomized trial has compared romosozumab with other bone agents using sexual function as a primary or secondary outcome. Looking at the evidence class by class helps set expectations.

Bisphosphonates

Alendronate, zoledronic acid, and risedronate have no documented direct effect on sex hormones. Observational data do not show excess sexual dysfunction versus untreated controls.

Denosumab

Denosumab (Prolia) blocks RANK-L to suppress osteoclast activity. Like romosozumab, it lacks any known mechanism for sex-hormone interference, and sexual dysfunction does not appear in its FDA-approved labeling. [10]

Teriparatide and Abaloparatide

Both PTH-receptor agonists can transiently raise serum calcium. Hypercalcemia at clinically significant levels can reduce libido and cause fatigue. However, at approved doses (teriparatide 20 mcg/day or abaloparatide 80 mcg/day), frank hypercalcemia is uncommon. Neither drug carries a sexual-function warning. [11]

Hormonal Agents

Estrogen-based therapy and the selective estrogen receptor modulator raloxifene do have direct effects on sexual function, estrogen supplementation generally improving vaginal lubrication and desire in postmenopausal women while raloxifene has a neutral-to-mixed effect. [12] Patients transitioning from hormonal therapies to romosozumab may notice changes in sexual symptoms that reflect withdrawal from estrogenic effects rather than anything romosozumab is doing.

Practical Counseling Points for Prescribers

When initiating romosozumab, address these areas to reduce patient confusion about sexual symptoms during the treatment year.

Before Starting

Set baseline expectations. Ask about current sexual function using a validated tool such as the Female Sexual Function Index (FSFI) or the PROMIS Sexual Function questionnaire. Document the score. If sexual complaints already exist, treat them concurrently rather than attributing future changes to the new medication by default.

The North American Menopause Society's 2022 position statement on sexual health notes that "genitourinary syndrome of menopause is underdiagnosed and undertreated, with fewer than 25% of affected women seeking care." [13] That treatment gap predates and outlasts any osteoporosis medication.

During the 12-Month Course

Monthly injection visits provide natural checkpoints. At months three, six, and nine, a brief verbal screen for new symptoms costs little time. If sexual complaints emerge, use the stepwise framework above before attributing causality to romosozumab.

After Completing Treatment

At month 12, romosozumab is stopped and an antiresorptive agent is started. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend transitioning to either denosumab or a bisphosphonate to preserve the BMD gains achieved. [14] At this transition point, reassess sexual function again. If complaints resolve after stopping romosozumab, that temporal association would warrant a case report or pharmacovigilance report to the FDA MedWatch program, as it could signal a previously undocumented effect.

Evidence Gaps and Future Research Directions

The honest clinical answer is that no randomized trial has specifically measured sexual function as an outcome in romosozumab-treated patients. Three research directions could fill this gap.

First, an analysis of the ARCH or FRAME patient-level datasets using validated sexual function questionnaires as outcomes would be feasible given the large sample sizes. Neither trial collected this data prospectively, but quality-of-life instruments used in those studies may contain relevant items.

Second, a mechanistic study measuring sclerostin levels in vaginal or vulvar tissue biopsies from postmenopausal women before and after romosozumab could clarify whether the drug reaches those compartments at biologically meaningful concentrations.

Third, real-world pharmacovigilance through FDA FAERS database analysis could quantify the reported rate of sexual adverse events for romosozumab compared with background reporting rates for other osteoporosis drugs. As of the most recent FAERS data reviewed for this article, sexual dysfunction adverse event reports for romosozumab remain below 0.1% of total reports, consistent with no signal. [15]